Skip to main content
. 2017 Dec 14;8:2129. doi: 10.1038/s41467-017-01929-y

Fig. 5.

Fig. 5

Perpetrator and victim behavior. Interaction network between the significant interactions from the exclusively joined Loewe Additivity and Bliss Independence-based GPDI analyses (a); arrows visualize direction of the PD interaction from the perpetrator drug to the victim drug, i.e., decrease of the victims EC50 resulting in antagonism (magenta) or increase of the victims EC50 resulting in synergism (turquoise); note that interactions can be mono-directional or bi-directional of same polarity (joint antagonism or joint synergy) or opposite polarity leading to asymmetric bidirectional interactions; frequency of perpetrator and victim behavior in the network is presented in b, to d. Abbreviations of the compounds: Aureobasidin A (AbA), Amphotericin B (AmB), Anisomycin (Ani), Benomyl (Ben), Bromopyruvate (Bro), CCCP (C3P), Calyculin A (Cal), Cantharidin (Can), Chlorzoxazone (Chl), Cisplatin (Cis), Clo (Clozapine), Cycloheximide (Cyc), Dyclonine (Dyc), Fenpropimorph (Fen), Haloperidol (Hal), Hygromycin (Hyg), Latrunculin B (Lat), Lithium (Lit), Methotrexate (Met), Methyl methanesulfonate (MMS), Myriocin (Myr), Pentamidine (Pen), Quinine (Qnn), Quinomycin (QMY), Radicicol (Rad), Rapamycin (Rap), Staurosporine (Sta), Tacrolimus (Tac), Tamoxifen (Tam), Tunicamycin (Tun), and Wortmannin (Wor)